Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
The new hospital is expected to open by March'24
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
The company exports mobile surgery equipment to over 100 countries from Pune
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Subscribe To Our Newsletter & Stay Updated
